{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:49:00Z","timestamp":1790840940453,"version":"4.1.0"},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0207915","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T14:02:49Z","timestamp":1543327369000},"page":"e0207915","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-2085","authenticated-orcid":true,"given":"Martina","family":"Korfei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stelmaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-6408","authenticated-orcid":true,"given":"BreAnne","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Skwarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashipavan","family":"Chillappagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Mahavadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soni S.","family":"Pullamsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"G Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and prevalence of idiopathic pulmonary fibrosis","volume":"174","author":"G Raghu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9779","key":"ref3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"PW Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"ref4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"L Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref5","article-title":"Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?","author":"C Hayton","year":"2017","journal-title":"Drugs Aging"},{"issue":"3","key":"ref6","first-page":"165","article-title":"Idiopathic pulmonary fibrosis: misunderstandings between epithelial cells and fibroblasts?","volume":"21","author":"M Selman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Diseases"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1753465810379801","article-title":"The pathogenesis of idiopathic pulmonary fibrosis","volume":"4","author":"WR Coward","year":"2010","journal-title":"Ther Adv Respir Dis"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model","volume":"189","author":"M Selman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"52","key":"ref9","doi-asserted-by":"crossref","first-page":"E1475","DOI":"10.1073\/pnas.1117988108","article-title":"Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition","volume":"108","author":"JR Rock","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pupt.2017.08.012","article-title":"Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts","volume":"46","author":"E Bouros","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"B Hinz","year":"2012","journal-title":"Am J Pathol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.2174\/092986709787846497","article-title":"Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast","volume":"16","author":"M Gharaee-Kermani","year":"2009","journal-title":"Curr Med Chem"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01941-2015","article-title":"Amplified canonical transforming growth factor-beta signaling via heat shock protein 90 in pulmonary fibrosis","volume":"49","author":"Z Sibinska","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"e86536","DOI":"10.1371\/journal.pone.0086536","article-title":"Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis","volume":"9","author":"SK Madala","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1165\/rcmb.2011-0237OC","article-title":"MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation","volume":"46","author":"SK Madala","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"e91454","DOI":"10.1172\/jci.insight.91454","article-title":"Hsp90 regulation of fibroblast activation in pulmonary fibrosis","volume":"2","author":"V Sontake","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bst0300211","article-title":"Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis","volume":"30","author":"DC Howell","year":"2002","journal-title":"Biochemi Soc Trans"},{"issue":"9","key":"ref18","first-page":"2550","article-title":"Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury","volume":"119","author":"CJ Scotton","year":"2009","journal-title":"J Clin Invest"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/emmm.201100604","article-title":"Genetic partitioning of interleukin-6 signaling in mice dissociates Stat3 from Smad3-mediated lung fibrosis","volume":"4","author":"RJ O\u2019Donoghue","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1096\/fj.15-273953","article-title":"STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation","volume":"30","author":"M Pedroza","year":"2016","journal-title":"FASEB J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pupt.2017.08.011","article-title":"Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study","volume":"46","author":"A Tzouvelekis","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"L Wollin","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"L Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel Mechanisms for the Antifibrotic Action of Nintedanib","volume":"54","author":"S Rangarajan","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13880209.2016.1247879","article-title":"Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models","volume":"55","author":"W Yu","year":"2017","journal-title":"Pharm Biol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"SN Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"ref27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"H Oku","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"2 Pt 1","key":"ref28","first-page":"L311","article-title":"Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level","volume":"276","author":"G Gurujeyalakshmi","year":"1999","journal-title":"Am J Physiol"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7150\/ijms.11579","article-title":"Role and New Insights of Pirfenidone in Fibrotic Diseases","volume":"12","author":"DA Lopez-de la Mora","year":"2015","journal-title":"Int J Med Sci"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12931-017-0600-3","article-title":"Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy","volume":"18","author":"Y Kurita","year":"2017","journal-title":"Respir Res"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/thoraxjnl-2014-206411","article-title":"Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis","volume":"70","author":"M Korfei","year":"2015","journal-title":"Thorax"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1038\/cddis.2013.146","article-title":"Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts","volume":"4","author":"SK Huang","year":"2013","journal-title":"Cell Death Dis"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1183\/09031936.00095113","article-title":"Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice","volume":"43","author":"YY Sanders","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2174\/1568026615666150813145800","article-title":"Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity","volume":"16","author":"SA Ganai","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hon.2462","article-title":"Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice","volume":"36","author":"MA Baertsch","year":"2018","journal-title":"Hematol Oncol"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1634\/theoncologist.2017-0184","article-title":"The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy","volume":"22","author":"K Tzogani","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"TA Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/OTT.S30773","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","volume":"6","author":"M Anne","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone Deacetylase Inhibitors as Anticancer Drugs","volume":"18","author":"T Eckschlager","year":"2017","journal-title":"In J Mol Sci"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1753465812436663","article-title":"Pirfenidone treatment of idiopathic pulmonary fibrosis","volume":"6","author":"A Azuma","year":"2012","journal-title":"Ther Adv Respir Dis"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"M Didiasova","year":"2017","journal-title":"FASEB J"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.yexcr.2015.11.013","article-title":"XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-beta1-stimulated C3H10T1\/2 cells via Smad2\/4","volume":"339","author":"SF Jin","year":"2015","journal-title":"Exp Cell Res"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress","volume":"115","author":"Y Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-016-0328-5","article-title":"Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis","volume":"17","author":"ST Lehtonen","year":"2016","journal-title":"Respir Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"E Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41374-017-0014-3","article-title":"Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro","volume":"98","author":"CL Hall","year":"2018","journal-title":"Lab Invest"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1593\/tlo.12271","article-title":"Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells","volume":"6","author":"R Montalbano","year":"2013","journal-title":"Transl Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2015.06.004","article-title":"beta-Arrestin-1 protects against endoplasmic reticulum stress\/p53-upregulated modulator of apoptosis-mediated apoptosis via repressing p-p65\/inducible nitric oxide synthase in portal hypertensive gastropathy","volume":"87","author":"S Tan","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"7\u20138","key":"ref49","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.biocel.2007.03.001","article-title":"Histone deacetylase inhibitors: signaling towards p21cip1\/waf1","volume":"39","author":"M Ocker","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jnutbio.2016.11.003","article-title":"Histone deacetylase 9 plays a role in the antifibrogenic effect of astaxanthin in hepatic stellate cells","volume":"40","author":"Y Yang","year":"2017","journal-title":"J Nutr Biochem"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2009.01.040","article-title":"Histone deacetylase inhibitors that target tubulin","volume":"280","author":"J Schemies","year":"2009","journal-title":"Cancer Lett"},{"issue":"27","key":"ref52","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1016\/j.biomaterials.2010.05.023","article-title":"Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures","volume":"31","author":"JS Strobl","year":"2010","journal-title":"Biomaterials"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"e97352","DOI":"10.1371\/journal.pone.0097352","article-title":"Dynamic rearrangement of F-actin is required to maintain the antitumor effect of trichostatin A","volume":"9","author":"DH Yang","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"ref54","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrm1682","article-title":"The actin cytoskeleton: a key regulator of apoptosis and ageing?","volume":"6","author":"CW Gourlay","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"44","key":"ref55","doi-asserted-by":"crossref","first-page":"45495","DOI":"10.1074\/jbc.M406933200","article-title":"CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells","volume":"279","author":"H Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"issue":"9","key":"ref56","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"A Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"H Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"issue":"22","key":"ref58","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"TE King Jr.","year":"2014","journal-title":"N Engl J Med"},{"issue":"129","key":"ref59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09059180.00003613","article-title":"Common pathways in idiopathic pulmonary fibrosis and cancer","volume":"22","author":"C Vancheri","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"30","key":"ref60","doi-asserted-by":"crossref","first-page":"48737","DOI":"10.18632\/oncotarget.17114","article-title":"The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis","volume":"8","author":"F Conforti","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"P Atadja","year":"2009","journal-title":"Cancer Lett"},{"issue":"6","key":"ref62","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2500\/ajra.2015.29.4221","article-title":"Pirfenidone inhibits transforming growth factor beta1-induced extracellular matrix production in nasal polyp-derived fibroblasts","volume":"29","author":"JM Shin","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"ref63","first-page":"A4940","article-title":"The effect of nintedanib compared to pirfenidone on serum-stimulated proliferation of human primary lung fibroblasts at clinically relevant concentrations","volume":"191","author":"L Wollin","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"ref64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pan.2012.02.013","article-title":"HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)","volume":"12","author":"O Mehdi","year":"2012","journal-title":"Pancreatology"},{"issue":"6A","key":"ref65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4236\/abb.2012.326085","article-title":"Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts","volume":"3","author":"TH Sisson","year":"2012","journal-title":"Adv Biosci Biotechnol"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"F996","DOI":"10.1152\/ajprenal.00282.2009","article-title":"Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy","volume":"297","author":"M Pang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ajpath.2011.12.022","article-title":"STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP\/IPF","volume":"180","author":"DV Pechkovsky","year":"2012","journal-title":"Am J Pathol"},{"issue":"17","key":"ref68","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1111\/bph.13929","article-title":"WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade","volume":"174","author":"YF Chuang","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"2","key":"ref69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"M Kortylewski","year":"2005","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"ref70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/01.LAB.0000032380.82232.67","article-title":"Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63","volume":"82","author":"M Chilosi","year":"2002","journal-title":"Lab Invest"},{"issue":"6","key":"ref71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12094-010-0527-3","article-title":"Epigenetic therapy of lymphoma using histone deacetylase inhibitors","volume":"12","author":"M Cotto","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00432-016-2229-x","article-title":"Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells","volume":"142","author":"N Mahendrarajah","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"ref73","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1002\/jcb.26133","article-title":"A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK\/STAT3 Signaling","volume":"118","author":"JH Nam","year":"2017","journal-title":"J Cell Biochem"},{"issue":"6","key":"ref74","doi-asserted-by":"crossref","first-page":"e90196","DOI":"10.1172\/jci.insight.90196","article-title":"Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations","volume":"2","author":"P Mondello","year":"2017","journal-title":"JCI Insight"},{"issue":"5707","key":"ref75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1108164","article-title":"Cell signaling. Stat acetylation\u2014a key facet of cytokine signaling?","volume":"307","author":"JJ O\u2019Shea","year":"2005","journal-title":"Science"},{"issue":"6","key":"ref76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cytogfr.2012.06.005","article-title":"Acetylation modulates the STAT signaling code","volume":"23","author":"M Wieczorek","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1\u20132","key":"ref77","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1007023532508","article-title":"Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals","volume":"204","author":"HP Misra","year":"2000","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"ref78","doi-asserted-by":"crossref","first-page":"e0186615","DOI":"10.1371\/journal.pone.0186615","article-title":"Tubastatin ameliorates pulmonary fibrosis by targeting the TGFbeta-PI3K-Akt pathway","volume":"12","author":"S Saito","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1074\/jbc.M115.713123","article-title":"Loss of alpha-Tubulin Acetylation Is Associated with TGF-beta-induced Epithelial-Mesenchymal Transition","volume":"291","author":"S Gu","year":"2016","journal-title":"J Biol Chem"},{"issue":"30","key":"ref80","doi-asserted-by":"crossref","first-page":"21065","DOI":"10.1074\/jbc.M802786200","article-title":"Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition","volume":"283","author":"B Shan","year":"2008","journal-title":"J Biol Chem"},{"key":"ref81","article-title":"Deletion of ApoM gene induces apoptosis in mouse kidney via mitochondrial and endoplasmic reticulum stress pathways","author":"W Pei","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"ref82","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jcb.21836","article-title":"Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway","volume":"105","author":"DO Croci","year":"2008","journal-title":"J Cell Biochem"},{"issue":"1","key":"ref83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11033-013-2856-0","article-title":"Transcriptional regulation of the survivin gene","volume":"41","author":"R Boidot","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"9","key":"ref84","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ijc.31199","article-title":"HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signaling in a subset of melanoma","volume":"142","author":"SJ Gallagher","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"ref85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbrc.2018.03.021","article-title":"Knockdown of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGFbeta pathway","volume":"498","author":"P Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"ref86","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbrc.2007.01.012","article-title":"Pirfenidone inhibits TGF-beta expression in malignant glioma cells","volume":"354","author":"I Burghardt","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"ref87","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-12-3180","article-title":"Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells","volume":"73","author":"S Kozono","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"ref88","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3892\/ol.2017.6188","article-title":"Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma","volume":"14","author":"R Kurimoto","year":"2017","journal-title":"Oncology Lett"},{"issue":"15","key":"ref89","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"C Polydorou","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"ref90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"56","author":"Y Miura","year":"2018","journal-title":"Respir Investig"},{"issue":"11","key":"ref91","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"JF San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"ref92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"KP Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"10","key":"ref93","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/QAD.0000000000000678","article-title":"The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients","volume":"29","author":"AS Hogh Kolbaek Kjaer","year":"2015","journal-title":"AIDS"},{"issue":"8","key":"ref94","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"MC Crisanti","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"ref95","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41598-017-01964-1","article-title":"A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC","volume":"7","author":"L Samaraweera","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"ref96","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/JTO.0b013e318293d88c","article-title":"A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer","volume":"8","author":"F de Marinis","year":"2013","journal-title":"J Thorac Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0207915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:19:34Z","timestamp":1775283574000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0207915"}},"subtitle":[],"editor":[{"given":"Gernot","family":"Zissel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0207915","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]}}}